NeOnc Raises $15M in At-the-Market Direct Offering with…

Event summary

NeOnc Technologies Holdings raised $15M via a registered direct offering priced at $4.20 per share.
The deal involved 3.57M shares (or pre-funded warrants) and accompanying warrants with new and existing institutional investors.
The offering is expected to close on September 10, 2026, subject to customary closing conditions.
Roth Capital Partners and A.G.P./Alliance Global Partners acted as co-placement agents.

The big picture

NeOnc’s $15M at-the-market offering reflects continued investor appetite for late-stage biopharmaceutical companies targeting CNS cancers. The deal underscores the strategic importance of overcoming the blood-brain barrier, a persistent challenge in oncology. With Phase 2 trials underway and FDA Fast-Track designation in place, NeOnc is positioning itself for potential pivotal studies, though execution risks remain high in this capital-intensive space.

What we're watching

Clinical Progress: How the $15M infusion will accelerate Phase 2 trials for NEO100 and NEO212.
Investor Confidence: Whether institutional backing signals sustained interest in CNS cancer therapies.
Execution Risk: The pace at which NeOnc can translate funding into regulatory milestones.